X

Trial Profile

Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics of Single Dose

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pirfenidone (Primary)
Indications Acute lung injury; Graft-versus-host disease; Heart failure; Idiopathic pulmonary fibrosis; Interstitial lung diseases; Lung transplant rejection; Pulmonary fibrosis; SARS-CoV-2 acute respiratory disease
Focus Pharmacokinetics
Sponsors Beijing Continent Pharmaceutical

Most Recent Events

09 Oct 2021 Planned End Date changed from 30 Dec 2021 to 30 Jun 2022.
09 Oct 2021 Planned primary completion date changed from 30 May 2021 to 30 Dec 2021.
23 Mar 2021 Planned End Date changed from 30 Nov 2020 to 30 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com